[{"id":"fc1c3f3a-6ae3-49f9-ae49-6cfdfa52a079","acronym":"","url":"https://clinicaltrials.gov/study/NCT02812875","created_at":"2022-01-05T23:59:52.244Z","updated_at":"2024-07-02T16:36:43.794Z","phase":"Phase 1","brief_title":"A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas","source_id_and_acronym":"NCT02812875","lead_sponsor":"Curis, Inc.","biomarkers":" VSIR","pipe":"","alterations":" ","tags":["VSIR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cenopodlin (CA-170)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 05/07/2020","primary_completion_date":" 05/07/2020","study_txt":" Completion: 05/07/2020","study_completion_date":" 05/07/2020","last_update_posted":"2020-06-26"}]